Aurora Cannabis Stock Falls as Canadian Producer Expects International Sales to Decline
June 18, 2025
Key Takeaways
- Aurora Cannabis stock dropped Wednesday as the company said it expects international sales to decline.
- The company’s U.S. traded shares lost about 17% of their value in recent trading but are still up significantly this year.
- Aurora said a slide in international sales is expected to offset growing medical cannabis sales in Canada.
Aurora Cannabis (ACB) shares tumbled Wednesday as the Canadian cannabis operator said it expects “temporary declines” in its international markets, which include the U.S.
The company’s U.S.-traded stock lost more than 17% of its value following the release of Aurora’s fiscal fourth-quarter results early Wednesday. Including the initial losses, shares are up roughly 14% for 2025.
Aurora said global cannabis revenue in the current quarter will likely decline from the company’s fourth-quarter level as reduced international sales offset growing Canadian medical cannabis sales.
The company posted quarterly revenue of 90.5 million Canadian dollars ($66.4 million), driven by medical cannabis sales that rose nearly 50% year-over-year to C$67.8 million. Its net loss narrowed to C$17.2 million from C$20.3 million in the year-ago quarter.
Search
RECENT PRESS RELEASES
Related Post
